- Home
- WNW vs IGC Comparison
WNW vs IGC Comparison
Compare WNW & IGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WNW | IGC |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.8M | 28.5M |
| IPO Year | 2019 | 2005 |
Fundamental Metrics
Financial Performance| Metric | WNW | IGC |
|---|---|---|
| Price | $1.75 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 10.0K | ★ 266.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,271,000.00 |
| Revenue This Year | N/A | $3.54 |
| Revenue Next Year | N/A | $15.12 |
| P/E Ratio | $1.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $0.24 |
| 52 Week High | $2.95 | $0.50 |
Technical Indicators
Market Signals| Indicator | WNW | IGC |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 53.55 |
| Support Level | $1.63 | N/A |
| Resistance Level | $1.89 | $0.32 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 74.51 | 41.58 |
Price Performance
Historical ComparisonAbout WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About IGC IGC Pharma Inc.
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.